GenSight Biologics S.A.
http://www.gensight-biologics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenSight Biologics S.A.
Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
EU Review Gets Under Way For Curative Vision Loss Gene Therapy
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Seeing Is Believing: New Approaches For Treating Eye Disorders
Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.
Regenerative Medicines And Advanced Therapies: Progress, Problems And Promise
The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy